Endpoints News 20 mar 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 26 feb 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News 18 feb 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News 12 ene 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Endpoints News 8 dic 2025 #ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?